IFM Therapeutics launches new spinout aimed at Parkinson’s, lupus and other diseases

Boston biotech IFM Therapeutic LLC is taking a second major step out from drug giant Bristol-Myers Squibb's wake this week, spinning out its second subsidiary focused on developing treatments for autoimmune and central nervous system diseases.

IFM Due (pronounced du-way) was launched Feb. 11 by the team behind IFM Therapeutics, which Bristol-Myers Squibb (NYSE: BMY) purchased in 2017 for $300 million upfront and upwards of $2 billion in milestone payments.

Expanding on its founders' efforts at…

Previous Meet tech vet Matt Harbaugh, the region's newest VC
Next Jackson Square Properties acquires Centennial Apartments for $74.5 million

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *